Clinical Trial Update: Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating genomic predictors of decitabine response in patients with acute myeloid leukemia or myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2018-10-02